Clinical Trials Sponsored by National Psoriasis Foundation

Total 2377 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Cervical Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

Endometrial Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Vaginal Changes and Sexual Function in Patients With Cervical Cancer

Cervical Cancer | Sexuality and Reproductive Issues

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Endometrial Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Sarcoma

United States, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Norway
Jinling Hospital, China
National Natural Science Foundation of China

Unknown

Early Jejunostomy Nutrition Minimizes Time to Chemotherapy

Laparoscopic Surgery | Gastric Cancer | Chemotherapy

China
Capital Medical University
National Natural Science Foundation of China

Completed

The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease

Cerebrovascular Disease

China
Royal Marsden NHS Foundation Trust

Unknown

Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia

Head and Neck Cancer | Xerostomia | Radiation Toxicity

United Kingdom
University Hospital, Geneva
Swiss National Science Foundation; Loterie Romande

Completed

Moxibustion for Fetus in Breech Presentation

Breech Presentation

Switzerland
Seoul St. Mary's Hospital
National Research Foundation of Korea

Recruiting

Liver Regional Oxygen Saturation in Preterm Patent Ductus Arteriosus

Premature Birth | Patent Ductus Arteriosus | Circulation | Newborn Morbidity

Korea, Republic of
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Samples From Patients With Endometrial Cancer

Lynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer

United States
Wonju Severance Christian Hospital
National Research Foundation of Korea

Completed

The Usefulness of Inflammatory Markers to Predict Poor Outcomes for Trauma Patients

Trauma Injury | Trauma, Multiple

Korea, Republic of
Dalian Medical University
National Natural Science Foundation of China

Completed

Construction of a Predictive Model of Gangrenous Cholecystitis Based on Machine Learning

Gangrenous Cholecystitis

China
Anhui Medical University
National Natural Science Foundation of China

Completed

Impact of Hepatectomy on HCC Recurrence (HCC)

Recurrence | Hepatocellular Carcinoma Stage I

China
National Jewish Health
Children's Hospital Colorado; Cystic Fibrosis Foundation

Enrolling by invitation

PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis (PATIENCE)

Cystic Fibrosis

United States
Indiana University
Merck Sharp & Dohme LLC; National Kidney Foundation

Completed

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

Chronic Kidney Disease | Dialysis

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection (GROINSS-V)

Stage III Vulvar Cancer | Vulvar Squamous Cell Carcinoma | Stage I Vulvar Cancer | Stage II Vulvar Cancer

United States, Canada
The Hospital for Sick Children
The National Pancreas Foundation

Withdrawn

CFTR Related Pancreatitis Study

Cystic Fibrosis | CFTR Gene Dysfunction
Wonju Severance Christian Hospital
National Research Foundation of Korea

Completed

Cardiac Magnetic Resonance Image (CMR) in Acute Carbon Monoxide (CO) Poisoning

Myocardial Injury | Carbon Monoxide Poisoning | Image, Body

Korea, Republic of
NHS National Waiting Times Centre Board
British Heart Foundation

Completed

CORonary MICrovascular Angina (CorMicA) (CorMicA)

Coronary Disease | Angina, Stable | Coronary Vasospasm | Microvascular Angina | Coronary Syndrome | Coronary Circulation

United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Ovarian Carcinoma

United States
Hangang Sacred Heart Hospital
National Research Foundation of Korea

Completed

Effects of Virtual Reality Based Rehabilitation on Burned Hands

Hand Injuries

Korea, Republic of
Hangang Sacred Heart Hospital
National Research Foundation of Korea

Completed

Frontal Lobe Oxyhemoglobin Levels in Patients With Lower Extremity Burns Assessed Using a fNIRS (fNIRS)

Walking

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Persistent Disease

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Psychological Impact of Cancer

United States
Sheffield Teaching Hospitals NHS Foundation Trust
National Osteoporosis Society

Completed

Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women

Vitamin D Deficiency | Osteoporosis

United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Sarcoma

United States, Japan
National University Hospital, Singapore
Janssen, LP; International Myeloma Foundation

Unknown

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Relapse and / or Refractory Myeloma

Singapore, Hong Kong, Taiwan, Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States

Clinical Trials Sponsored by National Psoriasis Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations